参考文献/References:
[1] Jansson MD, Lund AH. MicroRNA and cancer[J]. Mol Oncol,2012, 6(6):590-610. DOI:10.1016/j.molonc.2012.09.006.
[2] Leidinger P, Hart M, Backes C, et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer:miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status[J]. Tumour Biol, 2016, 37(8):10177-10185. DOI:10.1007/s13277-016-4883-7.
[3] Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer[J]. Cancer Res, 2007, 67(13):61306135. DOI:10.1158/0008-5472.CAN-07-0533.
[4] Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop[J]. J Biol Chem, 2007, 282(4):2135-2143. DOI:10.1074/jbc.M608939200.
[5] Zeng Y. Principles of micro-RNA production and maturation[J]. Oncogene, 2006, 25(46):6156-6162. DOI:10.1038/sj.onc.1209908.
[6] Catto JW, Alcaraz A, Bjartell AS, et al. MicroRNA in prostate, bladder, and kidney cancer:a systematic review[J]. Eur Urol, 2011, 59(5):671-681. DOI:10.1016/j.eururo.2011.01.044.
[7] Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30):10513-10518. DOI:10.1073/pnas.0804549105.
[8] Brase JC, Johannes M, Schlomm T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer[J]. Int J Cancer, 2011, 128(3):608-616. DOI:10.1002/ijc.25376.
[9] Yaman Agaoglu F, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer[J]. Tumour Biol, 2011, 32(3):583-588. DOI:10.1007/s13277-011-0154-9.
[10] Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum miRNAs on an oligonucleotide microarray[J/OL]. PLoS One,2009,4(7):e6229[2016-11-02]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704963/.DOI:10.1371/journal.pone.0006229.
[11] Selth LA, Townley S, Gillis JL, et al. Discovery of circulating micro RNAs associated with human prostate cancer using a mouse model of disease[J]. Int J Cancer, 2012, 131(3):652-661. DOI:10.1002/ijc.26405.
[12] Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer[J]. Urology, 2010, 77(5):1265.e9-1265.e16. DOI:10.1016/j.urology.2011.01.020.
[13] Moltzahn F, Olshen AB, Baehner L, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients[J]. Cancer Res, 2011, 71(2):550-560. DOI:10.1158/0008-5472.CAN-10-1229.
[14] Heneghan HM, Miller N, Kelly R, et al. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease[J]. Oncologist, 2010, 15(7):673-682. DOI:10.1634/theoncologist.2010-0103.
[15] Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2[J]. Med Oncol. 2012,29(2):815-822. DOI:10.1007/s12032-011-9934-8.
[16] Chen ZH, Zhang GL, Li HR, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer[J]. Prostate, 2012, 72(13):1443-1452. DOI:10.1002/pros.22495.
[17] Shen J, Hruby GW, Mckiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer[J]. Prostate, 2012, 72(13):1469-1477. DOI:10.1002/pros.22499.
[18] Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer[J]. Br J Cancer, 2012, 106(4):768-774. DOI:10.1038/bjc.2011.595.
[19] Hessvik NP, Phuyal S, Brech A, et al. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells[J]. Biochim Biophys Acta, 2012, 1819(11/12):1154-1163. DOI:10.1016/j.bbagrm. 2012.08.016.
[20] Liao H, Xiao Y, Hu Y, et al. microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells[J]. Oncol Lett, 2015, 10(4):2055-2062. DOI:10.3892/ol.2015. 3551.
[21] Hatano K, Kumar B, Zhang Y, et al. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation[J]. Nucleic Acids Res, 2015, 43(8):4075-4086. DOI:10.1093/nar/gkv273.
[22] Leung CM, Li SC, Chen TW, et al. Comprehensive microRNA profiling of prostate cancer cells after ionizing radiation treatment[J]. Oncol Rep, 2014, 31(3):1067-1078. DOI:10.3892/or.2014. 2988.
[23] Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer:a new paradigm for cancer gene therapy?[J]. Cancer Gene Ther, 2008, 15(6):341-355. DOI:10. 1038/cgt. 2008. 8.
[24] Griveau A, Bejaud J, Anthiya S, et al. Silencing of miR-21 by locked nucleic acid-lipid nanocapsule complexes sensitize human glioblastoma cells to radiation-induced cell death[J]. Int J Pharm, 2013, 454(2):765-774. DOI:10. 1016/j. ijpharm. 2013.05.049.
[25] 刘佳, 高刚, 朴春南, 等. 调节肿瘤放射敏感性的miRNAs研究进展[J]. 国际放射医学核医学杂志, 2016, 40(2):159-164. DOI:10.3760/cma.j.issn.1673-4114.2016.02.015. Liu J, Gao G, Piao CN, et al. Progress of microRNAs in regulating tumor radiation sensitivity[J]. Int J Radiat Med Nucl Med, 2016, 40(2):159-164.
[26] Zhang P, Wei Y, Wang L, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1[J]. Nat Cell Biol, 2014, 16(9):864-875. DOI:10.1038/ncb3013.
[27] Gong P, Zhang T, He D, e t al. MicroRNA-145 modulates tumor sensitivity to radiation in prostate cancer[J]. Radiat Res, 2015, 184(6):630-638. DOI:10.1667/RR14185.1.
[28] Xue G, Ren Z, Chen Y, et al. A feedback regulation between miR-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation[J]. Cancer Lett, 2015, 361(1):121-127. DOI:10.1016/j.canlet.2015.02.046.
[29] Mao A, Liu Y, Wang Y, et al. miR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells[J]. Tumour Biol, 2016, 37(4):4831-4840. DOI:10.1007/s13277-015-4336-8.
[30] Mao A, Zhao Q, Zhou X, et al. MicroRNA-449a enhances radiosen-sitivity by downregulation of c-Myc in prostate cancer cells[J/OL]. Sci Rep, 2016, 6:27346[2017-11-02]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890029/.DOI:10.1038/srep27346.
[31] Weber JA, Baxter DH, Zhang SL, et al. The MicroRNA spectrum in 12 body fluids[J]. Clin Chem, 2010, 56(11):1733-1741. DOI:10. 1373/clinchem.2010.147405.
[32] Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins[J]. Nat Cell Biol, 2011, 13(4):423-433. DOI:10. 1038/ncb2210.
[33] Tavoosidana G, Ronquist G, Darmanis S, et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer[J]. Proc Natl Acad Sci U S A, 2011, 108(21):8809-8814. DOI:10.1073/pnas.1019330108.
[34] Sorensen KD,orntoft TF. Discovery of prostate cancer biomarkers by microarray gene expression profiling[J]. Expert Rev Mol Diagn, 2010, 10(1):49-64. DOI:10.1586/erm.09.74.
[35] Ozen M, Creighton CJ, Ozdemir M, et al. Widespread deregulation of microRNA expression in human prostate cancer[J]. Oncogene, 2008, 27(12):1788-1793. DOI:10.1038/sj.onc.1210809.
[36] Rice MA, Ishteiwy RA, Magani F, et al. The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related[J]. Oncogene, 2016, 35(36):4752-4761. DOI:10.1038/onc.2016.6.
[37] Fabris L, Ceder Y, Chinnaiyan AM, et al. The Potential of MicroRNAs as Prostate Cancer Biomarkers[J]. Eur Urol, 2016, 70(2):312-322. DOI:10.1016/j.eururo.2015.12.054.
[38] Leidinger P, Hart M, Backes C, et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer:miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status[J]. Tumor Biol, 2016, 37(8):10177-10185. DOI:10.1007/s13277-016-4883-7.
相似文献/References:
[1]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[2]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[3]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[4]刘辰,杨悦,张雪宁,等.MRI和1997年版Partin表对前列腺癌病理特征预测准确性的对比研究[J].国际放射医学核医学杂志,2015,39(2):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
Liu Chen,Yang Yue,Zhang Xuening,et al.Accuracy of MRI and 1997 edition of Partin tables in predicting the pathological features of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
[5]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[6]张晖,段清,卓娜,等.经直肠超声引导下“6+X”点法前列腺穿刺活检诊断前列腺癌的临床价值分析[J].国际放射医学核医学杂志,2015,39(4):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
Zhang Hui,Duan Qing,Zhuo Na,et al.Meta-analysis of the diagnostic value of transrectal ultrasound-guided “6+X” points biopsy in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
[7]张龙敏,刘爱连.前列腺癌MRI诊断技术研究进展[J].国际放射医学核医学杂志,2014,38(1):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
Zhang Longmin,Liu Ailian.Advances in MRI diagnosis of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
[8]刘辰,杨悦,张雪宁,等.CT/MRI图像融合在前列腺癌IMRT中的应用进展[J].国际放射医学核医学杂志,2014,38(4):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
Liu Chen,Yang Yue,Zhang Xuening,et al.CT/MRI image fusion in intensity modulated radiation therapy for prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
[9]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[10]韦赐秋.中老年男性血清前列腺特异性抗原测定的临床价值[J].国际放射医学核医学杂志,2010,34(5):302.[doi:10.3760/cma.j.issn.1673-4114.2010.05.014]